Analyst Julian Harrison from BTIG maintained a Buy rating on Connect Biopharma Holdings and keeping the price target at $10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison’s rating is based on the promising potential of Connect Biopharma Holdings’ key drug, rademikibart, particularly in the treatment of acute asthma and COPD. The drug has demonstrated a rapid onset of effect, which is crucial for acute conditions, and has shown significant improvement in lung function and asthma control in clinical trials. This positions rademikibart as a strong competitor in the market, especially given its potential advantages over existing treatments like Dupixent.
Additionally, Connect Biopharma Holdings has a strategic partnership with Simcere in China, which could lead to substantial milestone payments and royalties. The company’s financial position is stable, with sufficient cash reserves to fund operations into 2027, further supporting the Buy rating. The ongoing development and potential approval of rademikibart in various markets, combined with a favorable valuation analysis, underpin the positive outlook for the stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.